CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Breast ductal lavage and fiberoptic ductoscopy coverage

This policy governs coverage determinations for breast ductal lavage and fiberoptic ductoscopy for detection, diagnosis, or management of breast disease, and applies to BCBSRI members and providers under the payer's Medicare Advantage and commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyBreast ductal lavage and fiberoptic ductoscopy coverage

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateSep 1, 2001

Next Review DateN/A

Key ActionDo not expect prior authorization; file claims with unlisted procedure code 19499 and be aware these procedures are typically not covered.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance (commercial & MA)

19499Unlisted CPT to bill

2001Policy effective

03/16/2022Last updated

Coverage Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage stances

Policy coverage statements by product:

Commercial Products - Ductal Lavage: Breast ductal lavage is considered not medically necessary because the evidence is insufficient to determine the effects of the technology on health outcomes in comparison to more established techniques for acquisition and evaluation of breast cytology.

Commercial product stance

Commercial Products - Fiberoptic Ductoscopy: Fiberoptic ductoscopy is considered not medically necessary for the detection, diagnosis, or treatment of breast cancer because the evidence is insufficient to determine the effects of the technology on health outcomes or to permit scientific conclusion regarding the role of breast duct endoscopy in evaluation and management.

Commercial product stance

Medicare Advantage Plans - Fiberoptic Ductoscopy: Fiberoptic ductoscopy is considered not covered for the detection, diagnosis, or treatment of breast cancer because the evidence is insufficient to determine the effects of the technology on health outcomes or to permit scientific conclusion regarding its role in evaluation and management.

MA product stance

Medicare Advantage Plans - Ductal Lavage: Breast ductal lavage is considered not covered, as the evidence is insufficient to determine the effects of the technology on health outcomes in comparison to more established techniques for acquisition and evaluation of breast cytology.

MA product stance

General Coverage Guidance: Benefits may vary between groups and contracts; refer to the appropriate benefit booklet, Evidence of Coverage, or subscriber agreement for member-specific coverage determinations.

Administrative guidance

Breast ductal lavage and fiberoptic ductoscopy are not covered / not medically necessary as described for the respective products. The policy states that evidence is insufficient to determine the effects of these technologies on health outcomes compared with established techniques for acquisition and evaluation of breast cytology, and therefore they are excluded from coverage or considered not medically necessary under the terms described below.

For Commercial products, breast ductal lavage is considered not medically necessary because the evidence is insufficient to determine its effects on health outcomes compared with established methods for obtaining and evaluating breast cytology. Similarly, fiberoptic ductoscopy is considered not medically necessary for detection, diagnosis, or treatment of breast cancer due to insufficient evidence to define its role in patient evaluation and management.

Provider Requirements and Impact

Prior Authorization

Prior authorization is not applicable for this policy.

Note

Benefit Variability

Benefits may vary by contract. Refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement to determine applicable coverage and whether procedures are considered not medically necessary or not covered under the member's plan.

Billing Rule

Billing with Unlisted CPT

There is no specific CPT code for breast ductal lavage or fiberoptic ductoscopy. File claims using the unlisted breast procedure code 19499.

19499 Unlisted procedure, breast

Denial Risk

Denial Risk for Ductal Lavage and Ductoscopy

Claims for ductal lavage and fiberoptic ductoscopy are at risk for denial because both procedures are considered not covered / not medically necessary under this policy.

Background and Rationale

Ductal lavage is a nonsurgical technique that collects ductal epithelial cells by cannulating nipple ducts with a microcatheter and flushing the duct with saline to retrieve cells for cytologic examination; it has been described as a “breast pap smear” and proposed as a risk-assessment or early-detection method in women at increased risk of breast cancer. Fiberoptic ductoscopy involves endoscopic visualization of the breast ductal system through the nipple orifice, allowing direct inspection and potential biopsy or therapeutic delivery within ducts. The policy cites a lack of sufficient controlled studies, uncertain diagnostic criteria for lavage specimens, and unclear impact on patient management as reasons these procedures are not covered or are considered not medically necessary.

Key Definitions

Ductal lavage — definition and brief description

TermDuctal lavage

DefinitionA method of collecting breast ductal epithelial cells for cytological analysis by inserting a microcatheter into milk ducts through the nipple orifices and flushing saline to wash out cells.

Intended useProposed as a risk assessment or early-detection tool for women at higher risk of breast cancer (eg, elevated Gail score, personal history, or BRCA mutation).

Key limitationInsufficient controlled studies and lack of consensus on cytological interpretation of lavage specimens, so effectiveness and impact on management are uncertain.

Fiberoptic ductoscopy — definition and brief description

TermFiberoptic ductoscopy

DefinitionEndoscopic examination of breast ducts achieved by cannulating the nipple orifice to directly visualize ductal epithelium, with capability for biopsy or therapeutic delivery.

Clinical uses exploredEvaluation of spontaneous nipple discharge, follow-up of atypical cytology from ductal lavage, delineation of ductal disease for surgical planning, and direct delivery of therapeutic agents.

Key limitationMinimal published information on how ductoscopy results affect subsequent management; evidence is insufficient to define its role in detection, diagnosis, or treatment of breast cancer.